Victory Capital Management
IKT icon

Victory Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Victory Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4K Buy
11,504
+952
+9% +$1.7K ﹤0.01% 2440
2026
Q1 		$17.7K Sell
10,552
-848
-7% -$1.51K ﹤0.01% 2378
2025
Q4 		$23.4K Buy
+11,400
New +$18.1K ﹤0.01% 2378

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Victory Capital Management's IKT Position: Q2 2026 in Review

Victory Capital Management increased its Inhibikase Therapeutics (IKT) stake by 9% in Q2 2026, buying an estimated $1.7K and bringing the position to 11,504 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Victory Capital Management first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $23.4K in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Victory Capital Management held 11,504 shares of Inhibikase Therapeutics worth $23.4K as of Q2 2026.
  • Victory Capital Management bought 952 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.7K.
  • Inhibikase Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2440 holding.
  • Victory Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Victory Capital Management's Inhibikase Therapeutics position peaked at $23.4K in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.